Pulmonary Disease clinical trials at UCSF
2 in progress, 1 open to eligible people
ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent
open to all eligible people
To demonstrate the safety and effectiveness of the Edwards Alterra Adaptive Prestent in conjunction with the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract/pulmonary valve (RVOT/PV) who are indicated for treatment of pulmonary regurgitation (PR). Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
San Francisco, California and other locations
DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers
Sorry, not currently recruiting here
DECAMP 1 PLUS aims to improve the efficiency of the diagnostic evaluation of patients with indeterminate pulmonary nodules (8-25 mm). Molecular biomarkers for lung cancer diagnosis measured in minimally invasive and non-invasive biospecimens may be able to distinguish between malignant or benign indeterminate pulmonary nodules in high-risk smokers. Ultimately, this study aims to validate molecular as well as clinical and imaging biomarkers of lung cancer in individuals with indeterminate lung nodules.
San Francisco, California and other locations
Last updated: